TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results

TG Therapeutics (NASDAQ:TGTX) issued its quarterly earnings data on Monday. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01), Briefing.com reports. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business’s quarterly revenue was down 49.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 earnings per share.

TG Therapeutics Trading Up 5.1 %

TGTX traded up $1.31 on Wednesday, reaching $27.17. 4,139,878 shares of the company traded hands, compared to its average volume of 3,650,948. TG Therapeutics has a one year low of $9.81 and a one year high of $27.67. The firm has a fifty day simple moving average of $23.57 and a two-hundred day simple moving average of $20.26. The company has a market cap of $4.21 billion, a P/E ratio of -258.60 and a beta of 2.19. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TGTX shares. HC Wainwright raised their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. B. Riley raised their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.